What will become of biotech in 2019? What’s the legacy of Sarepta Therapeutics? And how do you say “overhyped” in Mandarin?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Ike Swetlitz joins us to discuss the IBM’s latest travails with Watson Health, the purportedly revolutionary technology that has quickly become a cautionary tale. Then, we look forward to 2019 and the major biotech stories we’ll be keeping an eye on throughout the year. Finally, Dr. Ed Kaye, CEO of Stoke Therapeutics, joins us to talk about his new company, relive his days at Sarepta, and, bravely, answer rapid-fire questions in a lightning round.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy